New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
05:36 EDTPSTIPluristem takes possession of, moves into new manufacturing facility
Pluristem Therapeutics announced that the company has taken possession of and is moving into its new state-of-the-art GMP facility. The facility allows for the production of mass quantities of PLacental eXpanded cells that possess the advantages of being grown utilizing Pluristem's patented 3D bioreactor technology. The new manufacturing facility will have the capability to produce different PLX product candidates with the potential capacity of over 150,000 doses annually. Additionally, if more indications are approved by regulators for clinical trials, this new facility will enable us to supply PLX cells to conduct these additional trials in parallel.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
05:30 EDTPSTIPluristem announce data showing PLX-R18 cells improve bone marrow transplant
Subscribe for More Information
February 19, 2015
12:50 EDTPSTIPluristem says NIH study of PLX-R18 statistically significant
Pluristem Therapeutics announced the results of a recently completed trial conducted by the U.S. National Institutes of Health to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation, the company said. It added, "The data also suggested that the treatment may potentially be able to shorten time to recovery."
February 18, 2015
09:10 EDTPSTIOn The Fly: Pre-market Movers
Subscribe for More Information
05:17 EDTPSTIPluristem Therapeutics reports 'significant' findings in NIH trial of PLX-R18
Pluristem Therapeutics announced the positive results of a recently completed trial conducted by the U.S. National Institutes of Health, or NIH, to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation. The data also suggested that the treatment may potentially be able to shorten time to recovery. High levels of radiation can destroy the body's ability to produce these three blood lineages, and rapidly regaining that capacity is a key factor in surviving the hematologic component of acute radiation syndrome, or ARS, a condition caused by high-dose irradiation that can involve severe, sometimes lethal damage to the bone marrow as well as other physiologic systems and organs. The objective of this latest trial was to investigate the mechanism of action behind the significant improvement in survival in irradiated mice treated with PLX-R18 that was demonstrated in the NIH's first efficacy study. The results of the current study indicate that intramuscular administration exerts a systemic healing effect on bone marrow, lending further support to the concept that Pluristem's cells work systemically via secretion of therapeutic proteins, although the cells themselves remain in the muscle into which they were initially injected. While additional animal trials are needed prior to FDA approval of PLX-R18 for use in ARS, no human trials would be required because product development is conducted under the FDA's Animal Rule.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use